Celcuity’s Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients

AI Briefing

• – Gedatolisib formulation for subcutaneous injection to be developed, with first patent application submitted to U.S. Patent and Trademark Office.
• – No meaningful summary available.
• – No additional information available.